Airbus Group Joins the CARMAT Board of Directors

Regulatory News :

CARMAT (Paris:ALCAR) (FR0010907956, ALCAR, PEA-PME eligible), the designer and developer of the world's most advanced total artificial heart project, aiming to provide a therapeutic alternative for people suffering from end-stage heart failure, today announces that, at its meeting of March 20, 2015, CARMAT’s Board of Directors decided to co-opt Mrs Anne-Pascale Guédon, representative of Matra Défense, a 100% subsidiary of Airbus Group, as a Director of CARMAT, thus replacing Mr Michel Finance, who is standing down, for the remaining duration of the latter’s mandate, i.e. until the conclusion of the Shareholders’ Meeting that will be asked to approve this co-option and to rule on the Company’s 2014 annual accounts.

With more than 25 years of international experience in investment and in Mergers & Acquisitions, since 2008 Anne-Pascale Guédon has been Vice President Finance Engineering at Airbus Group, where she is responsible for managing funds to invest worldwide, via joint ventures or acquisitions, in core related businesses in order to establish a long-term footprint in countries of strategic interest to the Group. She is on the Board of the companies thus invested in. Before joining Airbus Group, Anne-Pascale Guédon held various executive positions within French companies (Bouygues, Loxam, Crédit Agricole) and international companies (GE Capital in London and Man Group in Hong Kong). She graduated from HEC and SFAF (the French society of financial analysts). Mrs Guédon is also an auditor of the 64^th national session of the IHEDN (National Institute for Defense Studies) and is a Colonel in the French Air Force reserve force. She has also been appointed Corporate Secretary of the BalanceforBusiness network, a recently-created global network that aims to promote diversity within Airbus Group.

Jean-Claude Cadudal, Chairman of CARMAT’s Board of Directors, comments: "We are delighted to welcome Anne-Pascale Guédon to CARMAT’s Board of Directors. Her financial expertise and in-depth knowledge of the industrial sector will be real assets for CARMAT’s strategic orientations. I would also like to sincerely thank Michel Finance for his contribution, which has gone far beyond that of a simple Director, notably within the framework of his two years as acting CEO of CARMAT in 2008 and 2009, but also for his chairmanship of our Audit Committee that has enabled the Group to ensure continual internal control and risk management procedures and real efficiency in the monitoring of its accounts and internal audit.”

???

About CARMAT: the world’s most advanced total artificial heart project

A credible response to end-stage heart failure: CARMAT aims to eventually provide a response to a major public health issue associated with heart disease, the world’s leading cause of death: chronic and acute heart failure. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from irreversible end-stage heart failure, the most seriously affected of the 20 million patients with this progressive disease in Europe and the United States.

The result of combining two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards^® heart valves, which are the most used in the world, and the technological expertise of Airbus Group, world aerospace leader.

Imitating the natural heart: given its size, the choice of structural materials and its innovative physiological functions, CARMAT’s total artificial heart could, assuming the necessary clinical trials are successful, potentially benefit the lives of thousands of patients a year with no risk of rejection and with a good quality of life.

A project leader acknowledged at a European level: with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by Bpifrance; a total of €33 million.

Strongly committed, prestigious founders and shareholders: Airbus Group, Professor Alain Carpentier, the Centre Chirurgical Marie Lannelongue, Truffle Capital, a leading European venture capital firm, and the thousands of institutional and individual shareholders who have placed their trust in CARMAT.

For more information: www.carmatsa.com

About Airbus Group
Airbus Group is a global leader in aeronautics, space and related services. In 2014, the Group – comprising Airbus, Airbus Defence and Space and Airbus Helicopters – generated revenues of €60.7 billion and employed a workforce of around 138,600.

???

Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in CARMAT ("the Company") in any country. This press release contains forward-looking statements that relate to the Company’s objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company’s management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. The Company’s objectives as mentioned in this press release may not be achieved for any of these reasons or due to other risks and uncertainties.
No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the Document de Référence filed with the Autorité des Marchés Financiers under number D.15-0138 on March 16, 2015, changes in economic conditions, the financial markets or the markets in which CARMAT operates. In particular, no guarantee can be given concerning the Company’s ability to finalize the development, validation and industrialization of the prosthesis and the equipment required for its use, to manufacture the prostheses, satisfy the requirements of the ANSM, enroll patients, obtain satisfactory clinical results, perform the clinical trials and tests required for CE marking and to obtain the CE mark. CARMAT products are currently exclusively used within the framework of clinical trials. They are not available outside these trials or for sale.

???

Name: CARMAT
ISIN code: FR0010907956
Ticker: ALCAR